Eli Lilly’s Next-Gen Obesity Drug Trounces Ozempic In Head-To-Head Test

Eli Lilly’s next-generation weight-loss drug, retatrutide, trounced Novo’s Ozempic in a head-to-head study, the company said Wednesday.

The post Eli Lilly’s Next-Gen Obesity Drug Trounces Ozempic In Head-To-Head Test appeared first on Investor’s Business Daily.